Treatment of Netherton Syndrome in Pediatrics with Upadacitinib

CONCLUSIONS: Initiation of Upadacitinib at a daily dose of 15 mg yielded significant therapeutic benefits within a short timeframe. This study marks the first documented use of Upadacitinib in pediatric Netherton syndrome treatment. This case highlights the efficacy of Upadacitinib in treating Netherton syndrome, particularly in pediatric patients. Further studies are warranted to elucidate its long-term effects and optimal dosing regimens.PMID:38607195
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Source Type: research